

Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison | defenseworld.net • |
BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX) | seekingalpha.com • |
Stocks Rally as Major Indexes Look to End Losing Streaks | schaeffersresearch.com • |
Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like | uk.sports.yahoo.com • |
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength? | zacks.com • |
Why BioCryst Pharmaceuticals Topped the Market Today | fool.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-08-04 | 2022-06 | -0.36 | N/A | N/A | N/A |
2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
2022-04-12 | RBC Capital | Upgrade | Sector Perform | |
2022-04-11 | B of A Securities | Downgrade | Buy | Neutral |
2022-04-11 | Oppenheimer | Upgrade | Outperform | |
2021-12-10 | Oppenheimer | Upgrade | Outperform | |
2021-11-04 | RBC Capital | Upgrade | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-03-30 | Blackrock Inc. | 14.10M | 229.30M | 7.60% |
2022-03-30 | Vanguard Group, Inc. (The) | 13.21M | 214.75M | 7.12% |
2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 206.68M | 6.85% |
2022-03-30 | FMR, LLC | 8.41M | 136.82M | 4.53% |
2022-03-30 | State Street Corporation | 7.46M | 121.34M | 4.02% |
2022-03-30 | Pictet Asset Management SA | 5.11M | 83.04M | 2.75% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 85.54M | 2.83% |
2022-04-29 | Fidelity Select Portfolios - Biotechnology | 4.19M | 38.95M | 2.26% |
2022-04-29 | iShares Russell 2000 ETF | 3.96M | 36.81M | 2.14% |
2022-04-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.71M | 34.50M | 2.00% |
2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 38.83M | 1.29% |
2022-03-30 | Vanguard Small-Cap Index Fund | 2.25M | 36.59M | 1.21% |
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
-
Please someone explain the sudden change in volume, in layman’s terms, Tysm
-
Please can someone explain the volume? I’m a newer trader. In layman’s terms. Tysm
-
Meant to say write. I misspelled because I’m so upset.
-
Write. Sorry. I can spell. Lol.
-
I am not a big time investor. I’m stuck in this pos stock. I’m now convinced more then ever this Company is Shady. I had 30 shares limit buy at 3.95. I saw it drop to pick it up then right back up. I don’t know much but I’m convinced this is rigged. It’s doing it again as I right this. Dipping down sudden then back up.
-
It’s going nowhere.
-
Any year now. Maybe 2022 will be the year
-
If Gladisvir was even possibly going to be a contender in Covid wouldn’t there be some shred of news out on that lately? I hope the positive hopes are correct but it feels like grasping at straws at this point. This stock needs to S—- or get off the pot. There’s just crickets on BCRX.
-
It just keeps getting better and better. Nightmare stock
-
Shady Shady something is not right here. Controlled stock. Live and learn. First dilution then you notice the pattern.
-
Manipulated stock. Want out. Waste of time.
-
Let’s be honest this stock is broken. NG
-
Same volume same price range day in and day out. Like watching paint dry
-
Why doesn’t this stock ever move? If I was even ,I’d get out and buy back later. It just shows no signs of life.
-
It’s just stuck! Zzzzz
-
Re Dexamethasone is all you need, that news states it’s for severe cases and patients are already vented. The key would be meds that treat you before you get to that point.
-
@Vafa sorry my words connected. Can’t find edit here.
-
@Vafabbut when will that news hit be? The last news didn’t do anything imo.
-
Company still selling shares at 4.50 target? They are still raising cash? How many shares do they have left to sell?
-
Each new day ends in hope for the next day. Trying hard to remain positive, too many over paid shares to turn back now. Frustrated. Bought before the dilution.
-
BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX)
seekingalpha.com • -
Stocks Rally as Major Indexes Look to End Losing Streaks
schaeffersresearch.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com • -
BioCryst Short-Sellers Lose Control
seekingalpha.com • -
BioCryst Shares Slide As Reddit-Induced Rally Peters Out
benzinga.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com •